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Abstract
Background: The spread of resistance to chloroquine (CQ) led to its withdrawal from use in most countries in
sub-Saharan Africa in the 1990s. In Malawi, this withdrawal was followed by a rapid reduction in the frequency of
resistance to the point where the drug is now considered to be effective once again, just nine years after its
withdrawal. In this report, the polymorphisms of markers associated with CQ-resistance against Plasmodium
falciparum isolates from coastal Kenya (Kilifi) were investigated, from 1993, prior to the withdrawal of CQ, to
2006, seven years after its withdrawal. Changes to those that occurred in the dihydrofolate reductase gene (dhfr)
that confers resistance to the replacement drug, pyrimethamine/sulphadoxine were also compared.
Methods: Mutations associated with CQ resistance, at codons 76 of pfcrt, at 86 of pfmdr1, and at codons 51, 59
and 164 of dhfr were analysed using PCR-restriction enzyme methods. In total, 406, 240 and 323 isolates were
genotyped for pfcrt-76, pfmdr1-86 and dhfr, respectively.
Results: From 1993 to 2006, the frequency of the pfcrt-76 mutant significantly decreased from around 95% to
60%, while the frequency of pfmdr1-86 did not decline, remaining around 75%. Though the frequency of dhfr
mutants was already high (around 80%) at the start of the study, this frequency increased to above 95% during
the study period. Mutation at codon 164 of dhfr was analysed in 2006 samples, and none of them had this
mutation.
Conclusion: In accord with the study in Malawi, a reduction in resistance to CQ following official withdrawal in
1999 was found, but unlike Malawi, the decline of resistance to CQ in Kilifi was much slower. It is estimated that,
at current rates of decline, it will take 13 more years for the clinical efficacy of CQ to be restored in Kilifi. In
addition, CQ resistance was declining before the drug's official withdrawal, suggesting that, prior to the official
ban, the use of CQ had decreased, probably due to its poor clinical effectiveness.
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Background
From the 1940s up to the 1990s, chloroquine (CQ) was
the mainstay of malaria therapy worldwide. The selection
of  Plasmodium falciparum-resistant isolates was first
reported in South-East Asia and South America in the
1950s [1] and by the 1970s, CQ was no longer effective in
these parts of the world. In Africa, CQ-resistant isolates
only emerged in the 1970s. However, within 10 years, the
level of resistance to CQ had risen rapidly [1], both in
southern and eastern Africa [2]. In 1993, Malawi was the
first African country to replace CQ as the first-line treat-
ment of uncomplicated malaria with the antifolate com-
bination sulphadoxine/pyrimethamine (SP) [3,4]. In
1999, Kenya also replaced CQ with SP [5]. Other coun-
tries, such as Uganda and Tanzania followed suit soon
after [6,7].
Recent studies in Malawi have indicated that CQ resist-
ance may revert to sensitivity within a decade of with-
drawal of the drug, based on analysis of the population
frequencies of the mutations known to cause or be associ-
ated with CQ resistance, pfcrt and pfmdr1 genes [3], and
assessment of in vitro activity and in vivo efficacy of the
drug [8,9]. This reversal indicates that the pfcrt mutants
may be loaded with a substantial fitness cost in the
absence of drugs, thus leading to their decline in fre-
quency once drug pressure is removed. This raises the pos-
sibility of re-introducing this safe and affordable drug for
treatment of malaria in Africa [4]. In this paper, are
reported the analyses of markers associated with CQ
resistance (pfcrt and pfmdr1) and the in vitro activity of CQ
against P. falciparum isolates collected in an area of high
transmission in coastal Kenya (Kilifi), from 1993, prior to
the removal of CQ, to 2006, seven years after its with-
drawal. In the same area, these changes that occurred in
the dihydrofolate reductase gene (dhfr), which confers
resistance to the replacement drug SP were also compared
[10,11].
Methods
Samples
A retrospective analasysis was carried out on blood sam-
ples collected from patients during several clinical trials of
anti-malarial drugs conducted in Kilifi from 1993 to
2006. The 1993–2003 samples originated from several
clinical trials of SP, chlorproguanil/dapsone (Lapdap™),
and SP-artesunate [12-15] and were collected before drug
treatment. Others were collected in 2006 from infected
patients both before and after treatment in clinical trials of
artemether/lumefantrine (AL)(Coartem™) versus piper-
aquine-dihydroartemisinin (Artekin®) [unpublished
data], and amodiaquine (AQ) [16]. No samples were col-
lected in 1996, 2004 and 2005. Blood samples (~50 μl)
were spotted onto filter paper, air-dried and stored in plas-
tic bags with silica gel at ambient temperature. Around
thirty samples were selected per year and analysed for P.
falciparum mutation at codon 76 (Lys to Thr) of pfcrt (pfcrt-
76) and at codon 86 (Asn to Tyr) of pfmdr1 (pfmdr1–86),
and at codons 51,59 and 164 of dhfr.
Parasite adaptation and drug assays
A subset of the 2006 samples were adapted in vitro for
long-term culture and their chemosensitivity profiles to
CQ were analysed. Briefly, parasite adaptation was carried
out as follows: 1 ml of patient venous blood was collected
and added to 5 ml of transport medium (RPMI-1640 con-
taining 10% albumin). Parasites in this medium could be
kept at 4°C for 4 days before the in vitro adaptation or cry-
opreserved in liquid nitrogen and adapted later. Fresh par-
asites were put in culture after washing the suspension
with normal RPMI-1640 (centrifugation at 2500 g for 15
min); cryopreserved parasites were thawed, washed and
put into in vitro culture according to standard protocols of
cryopreservation [16]. Parasitaemias were monitored
until a per cycle increase in parasitaemia greater than two-
fold was reached, at which point the culture was diluted
by a factor >2 and if parasitaemia increased again (greater
than two-fold), the culture was then considered
"adapted": this process lasted two to eight weeks. Once
parasites were adapted, their chemosensitivity to CQ was
determined by the radioisotope incorporation method
[17]. Results were expressed as the drug concentration
required for 50% inhibition of [3H] hypoxanthine incor-
poration into parasite nucleic acid (IC50), using regression
analysis of the dose-response curve. Fifty microlitres of
culture from these adapted parasites was spotted onto fil-
ter paper for DNA extraction and genotyping.
Genotyping
Parasite genomic material from filter paper was prepared
using the methanol procedure described elsewhere [18].
The detection of single-base changes at pfcrt-76  and
pfmdr1–86  was carried out using the PCR-restriction
enzyme protocol described elsewhere [3]. Point muta-
tions in codons 51, 59 and 164 of dhfr were analysed as
described elsewhere [18,19]. The analysis of mutations at
codon 164 of dhfr of samples was not carried out rou-
tinely, since previously reports showed that this mutation
was not present at detectable levels in our study site and
other African sites where SP resistance is high [20,21].
However, in light of reports on the emergence of 164 dhfr
mutant in Africa [22-24], the 164 codon of dhfr in isolates
collected in 2006 was analysed. Mutation at codon 108
was not analysed since the presence of a mutation at
codon 51 and/or 59 indicates that the parasite carries the
resistant mutation at codon 108 [10,11].
Statistical analyses
Frequencies of mutations at pfcrt-76, pfmdr1–86 and dhfr
(codons 51 and 59) alleles were calculated as the propor-Malaria Journal 2009, 8:106 http://www.malariajournal.com/content/8/1/106
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tion of samples carrying the mutant form out of the total
of all samples carrying either only the mutant form or
only the wild-type form: thus samples carrying both wild-
type and mutant forms, in which relative frequencies
could not be determined, were excluded from the denom-
inator and numerator. In the case of dhfr, those samples
with either a mutation at dhfr-51 (from the amino acid
Asn to Ile) or dhfr-59 (from Cys to Arg) were denoted as
'double mutants'. Those with mutations at both dhfr-51
and dhfr-59 were denoted as 'triple mutants' and those
with or without a resistant allele mutation at dhfr-108 (Ser
to Asn) were pooled and denoted as wild-type/single
mutants ('WT/single mutants'). The data were first ana-
lysed by treating these as three haplotypes, and then by
treating the double mutant forms as two separate alleles to
give four haplotypes.
As some of the samples were collected from patients
enrolled in clinical trials, an analysis was performed to
determine the potential bias to population frequencies
caused by drug treatment of the patients from which the
parasites were sampled. This was done by comparing the
frequencies of each mutant before versus after drug treat-
ment using a Fisher's Exact test for each trial separately.
Thereafter, an analysis was carried out for trends in the fre-
quencies of mutants through time with and then without
the post-treatment samples included in the data, by fitting
a logistic regression model to the frequency data with gen-
eration as a linear covariate and assuming three parasite
generations per year (an average of previously used esti-
mates [25,26] and consistent with estimates of durations
of infection in children [27]). The selection coefficient, s,
which describes how much more (or less) fit the resistant
mutant is relative to the wild-type, and is a function of the
amount of drug pressure and also the cost of resistance in
the absence of drug pressure [28], was calculated from the
estimated slope of the logistic regression curve fitted to the
observed allele frequencies over the generations, viz:
where the slope of this line is  [29], wR
and wS are the fitnesses of the resistant and wild-type alle-
les, respectively, 'log' denotes the natural logarithm, pR
and pS are the relative population frequencies of the resist-
ant and wild-type allele with pR = 1-pS, and the superscripts
denote the generation number. Solving for s is straightfor-
ward in the case of two alleles, but in the case of more alle-
les, as for dhfr, this equation cannot be directly used to
estimate the selection coefficient because it gives the fit-
ness of one allele relative to all other alleles combined. In
this case, the expected slope for allele i (slopei) becomes
 giving rise to allelic fitnesses of:
with i = 1,2,3 for single/WT, double and triple mutants,
respectively, and where j denotes all alleles other than i.
After setting w1 = 1, Equation (2) can be solved for w2 and
w3 by substituting in the observed values for pi and pj and
minimizing the sum of squared differences between the
observed slopei's (i.e., those obtained by logistic regres-
sion) and their expected values, (i.e., those in Equation
(2)). Note, however, that wi now depends on the frequen-
cies of the other alleles: since these change with time,
Equation (2) is an approximation [30]. In the case of dhfr
in this study, the single and double mutants changed rel-
atively little with time and so the approximation is likely
to be accurate.
Confidence intervals (95%) on estimates of s were calcu-
lated by taking the upper and lower CI values of the
regression estimates of the slope and then transforming
them using Equation (1). Significance levels of differences
between rates of decline of different alleles between differ-
ent time periods, and when including vs. excluding post-
treatment samples, were tested by t-tests. data from a pre-
viously published study in Malawi [3] were analysed in
the same manner. However, in that study, the frequencies
of resistant mutants were calculated as the proportion of
all samples with both single and mixed genotypes that
carried the resistant allele, either alone or with wild-type
alleles. Thus estimates of population allele frequency of
the mutants in that study are over-estimates.
Results
Four hundred and six, 240 and 323 isolates were geno-
typed for pfcrt-76, pfmdr1–86 and dhfr, respectively, col-
lected between 1993 and 2006 in Kilifi. Of these, 41, 28
and 58 carried mixed alleles and were not used in the
analysis. Data on pfcrt genotypes from patients that had
been treated with AQ (in 2006) were excluded because
post-treatment patients harboured a significantly higher
frequency of the pfcrt-76  mutant than pre-treatment
patients (19/19 vs. 19/31, P = 0.002). There was also an
indication that AL selected against the pfcrt mutant allele
(frequencies of 6/8 pre-treatment vs. 2/7 post-treatment, P
= 0.13). There were no significant effects of any other
drugs used in the clinical trials on pfmdr-86 and dhfr allele
frequencies. Nor did the inclusion of these post-treatment
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samples alter the slope of the regression lines in analyses
of time trends in allele frequencies. Nevertheless, for the
final analyses of time trends, Data from post-treatment
samples were excluded. The total number of samples in
these analyses was 322, 169 and 248 for pfcrt, pfmdr and
dhfr, respectively, with medians of 29, 20 and 23 per year
(Additional file 1).
Pfcrt-76 and pfmdr1–86
In Kilifi, the frequency of the pfcrt-76 mutant significantly
decreased (P < 0.001) from around 94% to 63% over a
period of 13 years (Figure 1a). This decline was occurring
before the official withdrawal of CQ in 1999 (P < 0.05).
There was no detectable difference in the rate of decline
before and after this time (P > 0.9 by test for an interaction
between the slope and time period). The estimated fitness
of this resistant mutant was 5% lower than that of the
wild-type (s = -0.05). In Malawi, the rate of decline after
CQ was withdrawn was much faster than in Kilifi (from
85% to 13% in 9 years). The estimated fitness of the resist-
ant mutant in the Malawi study was 12% lower than that
of the wild-type (s = -0.12): this was significantly greater
in magnitude than that in the Kilifi study (P < 0.001, by
Student's t-test of the logistic regression slopes).
pfmdr-86 did not decline significantly (P = 0.6) in the Kilifi
population (Figure 1b), and had a corresponding small
selection coefficient of 1%. On the other hand, in the
Malawi population, the frequency of the pfmdr1 mutant
allele decreased slightly (P  = 0.05) with an estimated
selection coefficient of -3%.
dhfr
In Kilifi, the frequency of the dhfr  double and triple
mutants combined was already high (around 80%) at the
start of the study (five years before SP became the first-line
treatment for uncomplicated malaria in Kenya). Nonethe-
less, this frequency increased significantly (P < 0.001) to
above 95% during the study period (Figure 2a). Relative
to the wild-type/single mutants, the triple and double
mutants combined had an estimated selection coefficient
of 7%. In contrast, the change in frequency in Malawi was
faster (from 15% to above 80% within nine years) with a
selection coefficient of 23% for the double and triple
mutants combined. This was significantly higher than that
for Kilifi (P < 0.001 by Student's t-test of the regression
slopes). No isolate had a mutation at 164 codon of dhfr.
Analysis of the mutant alleles separately in the Kilifi data
showed that the selection coefficients of the dhfr Asn51Ile-
Cyst59Arg double mutants were 5% and 7%, respectively,
and 8% for the triple mutant. The frequencies of the dou-
ble mutants stayed approximately the same through time
because, at the same time as they were gaining ground to
the wild-type/single mutant, they were losing ground to
the triple mutant (Figure 2b). The values of s found here
span the range of estimates from other sites in Africa and
South-East Asia [31]. The effect of including mixed infec-
tions on estimates of s was negligible. Thus the inability to
detect alleles at low frequencies within a patient sample
by the genotyping methods used here is unlikely to influ-
ence the results.
Prediction of pfcrt, pfmdr1 and dhfr allele frequencies in 
the future
Based on the above estimates and Equation (1), it is pre-
dicted that, if the current drug pressure were to be main-
tained, Kilifi isolates will have largely reverted to CQ-
sensitive phenotypes (frequency of the pfcrt-76  mutant
less than 10%) by the year 2023, over 20 years after the
official removal of the drug in Kenya. This contrasts with
the case in Malawi where this level of sensitivity was
reached within nine years following CQ withdrawal. In
Kilifi, virtually no change is expected in pfmdr1–86 fre-
quency while in Malawi by 2009, the frequency of
pfmdr1–86 mutant is expected to fall below 10%.
In vitro activity
CQ IC50  against laboratory reference strains V1S, W2
(pfcrt-76 mutant) and 3D7 and M24 (wild type) were ana-
lysed and and these IC50 values are 158 ± 75, 94.15 ± 16,
6.5 ± 2.3, 15.6 ± 8.6 nM respectively. The results of field
isolates are summarized in Figure 3. Depending on their
pfcrt-76 genotypes, parasites can be classified into three
distinct groups. The first group, the wild-type group, has
IC50 values ranging between 1 and 25 nM, with an average
of 13 ± 12 nM. The second group is composed of mixed
genotype infections (wild-type and mutant), with a mean
of 24 ± 10 nM; and the third group of pfcrt-76 mutants,
which forms the majority of isolates, has a mean of 63 ±
90 nM (ranging from 5 to 150 nM). To distinguish CQ-
sensitive and CQ-resistant isolates, a cut-off point of 100
nM is generally used [32,33]. However, using this cut-off
point, most isolates would be classified as CQ-sensitive,
yet they are pfcrt-76 mutant. Thus, the most accurate cut-
off point to use in our setting would be 25 nM (Figure 3).
The analysis of pfmdr1–86 genotype showed that wild-
type isolates had lower CQ IC50 than mutant (57 ± 50 nM
versus 68 nM+87 nM), but this difference was not statisti-
cally significant (p > 0.05).
Discussion
The results show that CQ resistance in Kilifi was in decline
since the early 1990s despite CQ only being officially
withdrawn from Kenya in 1999 [5] when it was replaced
by SP. In Kilifi District, this replacement was effective,
largely owing to an educational programme for rural drug
retailers during the change-over period in 1998 to 2001,
which raised the proportion of drug users that purchased
adequate doses of the first-line drug over-the-counterMalaria Journal 2009, 8:106 http://www.malariajournal.com/content/8/1/106
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Observed and fitted (by logistic regression) frequencies of pfrt-76 and pfmdr1–86 through time in Kilifi, Kenya and a study in  Malawi [3] Figure 1
Observed and fitted (by logistic regression) frequencies of pfrt-76 and pfmdr1–86 through time in Kilifi, Kenya 
and a study in Malawi [3]. Observed (symbols) and predicted (lines) population frequencies through time of alleles pfcrt-76 
(top panel) and pfmdr1–86 (bottom panel) involved in resistance to chloroquine in Kenya (solid line, closed symbols) and 
Malawi (dashed line, open symbols) before and after the official ban on the use of chloroquine (1999 and 1992, respectively). 
The P-value indicates whether the slope of the predicted line is significantly different from zero. The selection coefficient (s) of 
the resistant allele relative to the wild-type allele is shown with its 95% confidence intervals for each location.Malaria Journal 2009, 8:106 http://www.malariajournal.com/content/8/1/106
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Observed and predicted frequencies of dhfr mutations through time in Kilifi, Kenya and a study in Malawi [3] Figure 2
Observed and predicted frequencies of dhfr mutations through time in Kilifi, Kenya and a study in Malawi [3]. 
Observed (symbols) and predicted (lines) population frequencies through time of alleles at the dhfr locus determining resist-
ance to pyrimethamine, one of the partner drugs in SP. This drug officially replaced CQ as the first line drug in 1990 and 1992 
in Kenya and Malawi, respectively: however, in Kenya, it was used as a second line drug prior to the change from CQ. In the 
upper panel, the data are for the frequency of the double and triple mutant alleles combined whereas in the lower panel, the 
alleles are treated separately (see Methods). Selection coefficients are expressed relative to the wild-type/single mutant geno-
type.Malaria Journal 2009, 8:106 http://www.malariajournal.com/content/8/1/106
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(OTC) from 8% to 64% [34]. Thus, following this success-
ful training programme, CQ was largely discontinued in
Kilifi, and replaced by a high usage of SP. In other sites in
Kenya, however, CQ remained available at the commu-
nity level as a drug for self-medication, even four years
after its withdrawal [35]. The rate of change before and
after the point of official withdrawal (2001) was not
detectably different (P > 0.05).
These results suggest that widespread clinical failure of
CQ prior to the ban drove people to use alternative drugs
such as SP (which was then the second line of treatment)
regardless of the prevailing official policy. This is sup-
ported by the high frequency of the dhfr double and triple
mutants in the Kilifi population from the early 1990s [18]
(Figure 2). Furthermore, prior to 2001, even though CQ
was the most used anti-malarial, in most cases this drug
was used at sub-therapeutic doses [34]. Thus it seems that
declining usage and low efficacy due to high rates of clin-
ical failure led to a decline in resistance well before its offi-
cial discontinuation.
The fact that the frequency of the mutant allele neverthe-
less declined before the ban during continued use of the
drug implies that there is a considerable cost of the pfcrt
mutation to the parasite in the absence of drugs as even a
small amount of drug pressure is sufficient to counteract
quite high fitness costs [28]. That this is the case is evident
from the 12% lower relative fitness estimated for Malawi
after the drug was completely withdrawn. The apparently
smaller relative fitness cost of 5% in Kilifi supports our
view that the drug also remained in circulation despite the
ban, although we consider alternative explanations
below.
The frequency of the pfmdr1 mutant did not significantly
decrease over time, and this could be explained by the
marginal role pfmdr1 plays in CQ-resistance compared to
Chloroquine in vitro activity and pfcrt-76 genotype Figure 3
Chloroquine in vitro activity and pfcrt-76 genotype. Relationship between chloroquine inhibitory concentration that kills 
50% of parasitaemia (IC50) as measured by 50% inhibition of [3H]hypoxanthine incorporation into parasite nucleic acid, and 
pfcrt genotype at codon 76 of isolates collected in 2006 in Kilifi. The dashed line indicates the cut-off level of 25 nM.
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pfcrt [36,37]. This is supported by the results of this study
showing that the pfmdr1 mutants do not have higher CQ
IC50s than wild type. However, in Malawi, over few years,
the frequency of pfmdr1 mutants significantly decreased,
and this may be due to a rapid decline of CQ-resistance.
Thus in Kenya, this may be observed when the pfcrt wild
type reaches a high frequency in the population.
It is well established that mutations that render an organ-
ism resistant to a drug are likely to be associated with a
loss of fitness. As a result, organisms carrying these muta-
tions will be outgrown by drug-sensitive organisms when
the drug pressure is removed or reduced [38-42]. An
increase in CQ in vitro activity and a decrease in prevalence
of pfcrt-76 was also observed after the withdrawal of CQ
in China [43,44]. Selection of CQ resistance was associ-
ated with a loss of fitness in murine malaria, and the same
phenomenon has been reported for other anti-malarial
drugs, such as pyrimethamine and atovaquone in P. falci-
parum [45-47]. In some instances, loss of fitness may be
associated with the development of compensatory mech-
anisms, leading to persistence of the mutant parasite in
the population despite the discontinuation of the drug.
This feature may explain, at least in part, the persistence of
pfcrt-76  mutant in parts of South-East Asia and South
America [48-50], and in Kilifi as described here, despite
CQ not having been used in these areas for many years.
The apparent difference between Kenya and Malawi in the
rate of disappearance may also have been due to different
usages rates of AQ, a close analogue to CQ. This and other
studies have demonstrated that the use of AQ can select
for the pfcrt-76 mutant [51]. AQ has been the second line
of treatment in Kenya since SP was introduced in 1999
and has remained so until now. This drug has partially
been used in several sites in Kenya [35], including Kilifi,
even before the withdrawal of CQ [34].
CQ in vitro activity of Kenyan isolates collected in 2006 in
this population were also tested. The data showed that the
cut-off point of 100 nM [33] commonly used to distin-
guish CQ-resistant isolates from CQ-sensitive ones is not
appropriate in our setting. We propose that 25 nM is a
more suitable cut-off point to use in Kilifi, which is much
lower than in other areas. The most likely explanation of
this low cut-off point is the variability of the chemosensi-
tivity assay in different settings due to the many factors
that influence it [32,52]. For example, here we used the
CQ-resistant strains V1S and W2 and the CQ-sensitive
M24 and 3D7 as controls. The observation of previous
reports show that CQ IC50 against these strains are 0.7
time lower to four times higher than IC50  values we
obtained, and in general, our IC50s against the CQ-resist-
ant strains V1S and W2 were at least 1.5 time lower
[32,53-59]. Thus, whilst the in vitro chemosensitivity assay
is a robust technique to discriminate between CQ-sensi-
tive and CQ-resistant isolates within a setting, there is a
need to define the cut-off point in every research setting
[32,60].
Conclusion
The current report demonstrates that CQ-resistance has
been decreasing in Kilifi since its withdrawal in 1999, but
that this decline was much slower than in Malawi. It will
take 13 more years for the clinical efficacy of CQ to be
restored in Kilifi. The most likely reason for this difference
is that the change of drug policy from CQ to SP in Malawi
was swift and effective, such that SP became the only
available anti-malarial drug for treatment within one year
of implementaiton. In Kenya, it appears that the ban was
both too late and was ineffectively applied, so that it gave
rise to the use of other drugs such as AQ, as well as contin-
ued use of CQ, thereby maintaining selection for CQ
resistance. Thus, while the highly efficient implementa-
tion of drug policy in Malawi that permitted a faster
reversal of CQ resistance also promoted more rapid selec-
tion for resistance against the replacement drug, SP, than
in Kenya, the less rigorous enforcement of drug policy in
Kenya has resulted in both the high maintenance of CQ
resistance as well as high SP resistance. Thus the effective-
ness of drug policy implementation can have important
and far-reaching effects on the useful life of life-saving
drugs. The newer policies of using drugs in combinations
in order to prolong the resistance-free period is a good
example of this [28,61].
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